Clinical Research Studies
Physicians and researchers at the Cancer and Bood Diseases Insitute of Cincinnati Children's Hospital Medical Center offer clinical research studies for patients with leukemia and lymphoma.
Acute Lymphoblastic Leukemia
Therapy for First Relapse
Therapy for New Diagnosis Very High Risk Disease
Therapy for Second or Greater Relapse
Acute Myeloid Leukemia and Myelodysplasia
Therapy for New Diagnosis High Risk Disease
Therapy for Relapse
Hodgkin's and Non-Hodgkin's Lymphoma
Therapy for Newly Diagnosed Lymphoma
Therapy for Relapse
- ADVL0612: A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children with Refractory Solid Tumors
- ADVL0714: A Phase I Study of VEGF Trap in Children with Refractory Solid Tumors
- ADVL0812: A Phase I Study of MLN8237, an Oral Selective Small Molecule Inhibitor of Aurora A Kinase, in Pediatric Patients With Relapsed/Refractory Solid Tumors and Leukemia
- AHOD0521: Phase II Pilot Study of Bortezomib, Ifosfamide, and Vinorelbine Ditartrate in Pediatric Patients and Young Adults With Refractory or Recurrent Hodgkin's Lymphoma
- NCI-07-C-0040: A Phase I Trial of the Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors
- VITAC: A Pilot Study of the Addition of Bevacizumab to Vincristine, Oral Irinotecan and Temozolomide (VOIT regiment) for Relapsed/Refractory Pediatric Solid Tumors
- AALL07P1: A Phase II Pilot Trial of Bortezomib (PS-341, Velcade®, IND #58,443) in Combination with Intensive Re-Induction Therapy for Children With Relapsed Acute Lymphoblastic Leukemia (ALL) and Lymphoblastic Lymphoma (LL)
